Quality Control and Calibration in HDL Cholesterol Testing: Ensuring Analytical Accuracy and Consistency

1. Why Quality Assurance Matters in HDL-C Testing

HDL cholesterol (HDL-C) is routinely measured as part of the lipid profile. Its clinical interpretation depends on analytical results that are consistent over time and suitable for the intended patient population. Even a well-designed enzymatic assay requires appropriate calibration, internal quality control (IQC) and documented verification on the analyzer in use.

Quality assurance is not a single test performed at installation. It is an ongoing system of preventive checks, monitoring, investigation and corrective action. This article focuses on how those principles apply to automated direct HDL-C assays and explains the relevant materials and operating instructions specified for Archem Diagnostics Direct HDL Cholesterol.

2. Calibration: Establishing the Measurement Relationship

Calibration establishes the relationship between an instrument response and an assigned analyte concentration. For HDL-C, the calibration process must follow the reagent-specific application parameters, calibrator instructions and analyzer software requirements.

A stated calibration stability interval is a conditional operating characteristic, not permission to disregard quality-control findings. Changes in reagent lots, major maintenance, control shifts or unacceptable control results may require recalibration or further investigation under the laboratory’s procedures.

Traceability and the assigned values of calibrator materials should be assessed using the documentation supplied for the specific material. A calibrator and a control have different purposes: the calibrator establishes the measurement relationship, while a control monitors whether the analytical process remains under control.

3. Internal Quality Control: Two Levels and Routine Monitoring

Internal quality control uses materials with expected concentrations to monitor the assay during routine operation. Running two levels helps assess performance at more than one concentration and can reveal concentration-dependent problems that a single control might miss.

For the Archem Direct HDL-C assay, the manufacturer’s IFU instructs laboratories to run at least two control levels once every 24 hours. Each laboratory is also expected to establish its own quality-control scheme and acceptance criteria. Additional controls may be appropriate after maintenance, reagent changes or when required by local procedures.

Control results should be reviewed before releasing affected patient results. Plotting results over time, for example on Levey–Jennings charts, can make trends, shifts and isolated outliers easier to detect.

4. Understanding Precision, Bias and Total Error

Precision describes the closeness of repeated measurements under specified conditions. Bias describes systematic deviation from a reference or comparative target. A laboratory must consider both when defining its analytical performance requirements.

A low coefficient of variation (CV) does not, by itself, demonstrate acceptable trueness. Likewise, a strong method-comparison correlation does not establish agreement or eliminate clinically meaningful bias. Quality goals should be defined before interpreting performance data.

The Archem HDL-C IFU reports within-run CV values of 0.60–1.01% and day-to-day CV values of 2.05–2.18% under its evaluation conditions. These are documented manufacturer study results, not a substitute for laboratory-specific verification.

5. Factors That Can Affect HDL-C Results

Potential sources of variation include inappropriate sample handling, reagent temperature, incomplete mixing, pipetting errors, optical problems, carry-over, reagent deterioration and unsuitable calibration settings. Instrument cooling performance is particularly relevant when evaluating on-board reagent stability.

Interfering substances and specimen characteristics must be considered using the current IFU and the laboratory’s patient population. Unexpected results should prompt a review of specimen integrity and analytical flags rather than automatic repetition without investigation.

Analyzer applications may differ in sample and reagent volumes, wavelengths, reaction timing and wash procedures. The fact that a platform is listed in a corporate validation center does not prove that every assay is validated for that model.

6. Archem HDL-C: Calibrator, Controls and Stability

The Archem Direct HDL Cholesterol assay is a ready-to-use, liquid two-reagent homogeneous enzymatic colorimetric method for quantitative measurement in human serum and plasma. Its IFU specifies the lyophilized HDL-LDL (Arcal Lipid) Calibrator for calibration.

For internal quality control, the IFU identifies Arcon N (Level 1) and Arcon P (Level 2), both lyophilized control materials. Commercial control material with values established for the method may also be used as described in the IFU.

The IFU reports a 30-day calibration stability period depending on analyzer application characteristics and cooling capacity. Opened reagent vials are described as stable for 30 days at 2–8°C under optimum conditions; on-board stability depends on analyzer cooling and carry-over. Reagents must be stored as directed and must not be frozen.

7. Responding to Out-of-Control Results

When a control result exceeds established acceptance limits, the laboratory should stop and evaluate the affected analytical process before releasing patient results. The investigation should be systematic rather than based on repeated testing until a value falls within range.

Possible checks include confirming control preparation and storage, examining reagent expiry and lot information, reviewing recent maintenance, inspecting pipetting or temperature issues and checking calibration status. The Archem IFU calls for recalibration when quality-control results are outside acceptable limits.

Following corrective action, the laboratory should document the cause where identifiable, repeat appropriate controls and assess whether previously reported results may have been affected. The exact response should follow the laboratory’s approved quality procedures.

8. Building a Sustainable Quality Management Workflow

An effective quality-control plan defines control frequency, concentration levels, target values, acceptable limits, review responsibilities, escalation steps and record retention. It should also specify what happens after reagent-lot changes, calibration events and analyzer servicing.

Periodic review of control trends and participation in an appropriate external quality assessment or proficiency-testing scheme can complement daily IQC. Neither replaces verification of the reagent–analyzer application before clinical use.

For direct HDL-C testing, consistent results come from the combination of validated procedures, suitable materials, instrument maintenance, trained personnel and documented review—not from any single reagent claim.